Zuga Matt 4

What Happened
Zuga Matt, CFO and Chief Business Officer of Acumen Pharmaceuticals (ABOS), sold a total of 4,160 shares in two open-market transactions to cover tax withholding on vested restricted stock units. On 2026-01-21 he disposed of 2,473 shares (reported value $4,469) and on 2026-01-22 he disposed of 1,687 shares (reported value $3,138), for total proceeds of about $7,607. These were sales (not purchases), and the filing indicates they were routine sell-to-cover transactions tied to RSU vesting.

Key Details

• Transaction dates and amounts:
  • 2026-01-21: 2,473 shares sold; reported proceeds $4,469.
  • 2026-01-22: 1,687 shares sold; reported proceeds $3,138.
  • Total: 4,160 shares sold for ~ $7,607.
• Price details: the reported prices are weighted averages; sales occurred at prices ranging from $1.7650 to $1.8700 (footnote F2). The filing states the weighted-average prices and offers to provide a breakdown on request.
• Footnotes:
  • F1: These were automatic "sell to cover" sales to satisfy tax withholding on RSU vesting, executed under a Rule 10b5-1 plan adopted by the reporting person on August 30, 2024.
  • F2: The reported price is a weighted average; individual trade prices fall within the stated range.
• Shares owned after the transactions: not specified in the information provided in this summary.
• Filing timeliness: Form filed 2026-01-23 — within the typical 2-business-day reporting window for Form 4 (not indicated as late).

Context
These sales were executed to cover taxes on vested restricted stock units under a pre-established Rule 10b5-1 plan, which is a common, routine reason for insider sales and does not, by itself, indicate a change in the insider’s view of the company. Purchases typically provide stronger signals than routine sell-to-cover transactions; this filing documents a tax-related disposition rather than an opportunistic market sale.